MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial Condition

19

MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

On October 10, 2017, MiMedx issued a press release announcing its revenues for the period ended September 30, 2017. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.

Item 7.01Regulation FD Disclosure

On October 11, 2017, MiMedx conducted an investor conference call that was webcast so that all shareholders might listen. However, the Company's webcast provider experienced technical difficulties during the call, and portions of the call may not have been available to persons listening by webcast rather than by telephone. A complete replay of the webcast is available on the Company's website, www.mimedx.com, at the "Investors" tab. The conference call provider was not able to furnish the Company a reasonably reliable transcript by the time this report was filed.

Item 9.01Financial Statements and Exhibits

(d)Exhibits

99.1MiMedx Group, Inc. press release dated October 10, 2017.


MIMEDX GROUP, INC. Exhibit
EX-99.1 2 a101020178-kex991revenuepr.htm EXHIBIT 99.1 Exhibit Exhibit 99.1                       PRESS RELEASE CONTACT: MICHAEL SENKENPHONE: (770) 651-9100MIMEDX ANNOUNCES THIRD QUARTER REVENUES OF $84.6 MILLION EXCEEDS GUIDANCE BY MORE THAN 5 PERCENT MIMEDX TO HOST CONFERENCE CALL ON WEDNESDAY,…
To view the full exhibit click here

About MIMEDX GROUP, INC. (NASDAQ:MDXG)

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.

An ad to help with our costs